Evidence map›Paper›PMID 27866590›Full record

ArticleNuclear medicine and biology2016

Corrigendum to the inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach [Nucl Med Biol 43 (2016) 215-225].

Frederick O Cope, Bonnie Abbruzzese, James Sanders, Wendy Metz, Kristyn Sturms, David Ralph, Michael Blue, Jane Zhang, Paige Bracci, Wiam Bshara and 26 more

2 registry-linked trialsAbstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nuclear medicine and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03157167 phase1completednot on this mapstarted 2017, after this paper: background citation

An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and a Comparison to Subcutaneous (SC) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)

TypeinterventionalSponsorNavidea BiopharmaceuticalsRan2017 to 2020Enrolled15ConditionsKaposi Sarcoma, HIV InfectionsArmsTc99m-tilmanocept
NCT03332940 phase1terminatednot on this mapstarted 2017, after this paper: background citation

An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC)

TypeinterventionalSponsorNavidea BiopharmaceuticalsRan2017 to 2019Enrolled6ConditionsNonalcoholic Steatohepatitis, NASH - Nonalcoholic SteatohepatitisArmsTc 99M Sulfur Colloid, Tc99m-tilmanocept
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors.

Frederick O CopeNavidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017. Electronic address: fcope@navidea.com.
Bonnie AbbruzzeseNavidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017.
James SandersNavidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017.
Wendy MetzNavidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017.
Kristyn SturmsNavidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017.
David RalphNavidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017.
Michael BlueNavidea Biopharmaceuticals, Drug Development, 5600 Blazer Parkway, Dublin, OH 43017.
Jane ZhangThe University of California San Francisco and the San Francisco General Hospital, AIDS and Cancer Specimen Resource Center, The Department of Pathology, 1001 Potrero Ave, Bldg. 3, Rm 207, San Francisco, CA 94110.
Paige BracciThe University of California San Francisco and the San Francisco General Hospital, AIDS and Cancer Specimen Resource Center, The Department of Pathology, 1001 Potrero Ave, Bldg. 3, Rm 207, San Francisco, CA 94110.
Wiam BsharaRoswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263.
Spencer BehrRoswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263.
Toby MaurerRoswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263.
Kenneth WilliamsBoston College, Department of Biology, 14 Commonwealth Ave, Chestnut Hill, MA 02467.
Joshua WalkerBoston College, Department of Biology, 14 Commonwealth Ave, Chestnut Hill, MA 02467.
Allison BeverlyNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Brooke BlayNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Anirudh DamughatlaNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Mark LarsenNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Courtney MountainNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Erin NeylonNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Kaeli ParcelNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Kapil RaghuramanNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Kevin RicksNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Lucas RoseNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Akhilesh SivakumarNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Nicholas StreckNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Bryan WangNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Christopher WascoNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Amifred WilliamsNavidea Biopharmaceuticals Drug Development Internship Program, 5600 Blazer Parkway, Dublin, OH 43017.
Larry S SchlesingerCenter for Microbial Interface Biology, The Ohio State University, Columbus, OH, 43210; The Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210.
Abul AzadCenter for Microbial Interface Biology, The Ohio State University, Columbus, OH, 43210; The Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210.
Murugesan V S RajaramCenter for Microbial Interface Biology, The Ohio State University, Columbus, OH, 43210; The Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210.
Wael JarjourDepartment of Internal Medicine, Division of Rheumatology and Immunology, The Ohio State University, Columbus, OH 43210.
Nicholas YoungDepartment of Internal Medicine, Division of Rheumatology and Immunology, The Ohio State University, Columbus, OH 43210.
Thomas RosolThe School of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.
Michael McGrathThe University of California San Francisco and the San Francisco General Hospital, AIDS and Cancer Specimen Resource Center, The Department of Pathology, 1001 Potrero Ave, Bldg. 3, Rm 207, San Francisco, CA 94110.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID27866590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.